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integrity. It is possible that this process has varying degrees
of severity. Growth factors and human cultured skin
(HCS) are two new therapies that have met with some
success in treating “difficult ulcers”.5,6 Unfortunately, the
definitions of difficult ulcers in these studies are inconsis-
tent and range from the initial size of the ulcer to resis-
tance to compression therapy. Well-defined criteria do not
exist to identify appropriate subpopulations of patients
who will benefit from these nonoperative modalities. In
any case, these therapies are expensive, and widespread use
is both impractical and unnecessary. If most venous ulcers
can be healed in 9 weeks with compression dressings, it
would be ideal to identify the remaining 30% early in their
course. This would save the patient weeks of ineffective
therapy in compression dressings before being labeled as
“refractory to therapy.”
Patients with chronic venous insufficiency (CVI) are
known to have a delayed wound healing capacity in the
affected limb. The mechanism for this delayed healing is
unknown. White blood cell trapping, macromolecular
leaking, and fibrin cuffing7-9 are some theories that
attempt to explain this reduced wound healing. Recent
work has demonstrated a link between CVI and the accel-
erated aging of fibroblasts isolated from the lower extrem-
ity of patients affected with CVI.10-12 Although the
pathophysiologic process is still ill defined, it appears that
long-standing venous insufficiency leads to premature
fibroblast aging. Aged or senescent fibroblasts have
reduced motility, have arrested capacity for multiplication,
respond poorly to growth factors, and have abnormal pro-
tein production.13,14 If CVI leads to premature aging of
cellular elements, therapies can be directed along these
Venous ulcerations are the result of a pathophysiologic
process, which to date has not been clearly described. Leg
elevation and compression dressings, which originated in
the late 1800s, remain the mainstay of nonoperative ther-
apy. These ulcers are indolent, and patients must be
treated with compression dressings for long periods of
time for the ulcers to heal. Mean healing times for treat-
ment with elastic stockings and local wound care are 5 to
6 months.1 Paste compression dressings have been found
to heal 70% of ulcers in a time period of 9 weeks.2,3 These
ulcers are frustrating for the clinician and the patient, and
although serious complications are rare, the morbidity is
long term because most patients with ulcers are prone to
recurrence.
Recent innovations in surgical therapy have allowed
for surgical correction of abnormal venous hemodynamics
with subfascial endoscopic perforator surgery.4 Duplex
examination with perforator mapping is currently used to
identify patient populations appropriate for this proce-
dure.
The slowed healing and characteristic location (gaiter
portion of the lower leg) demonstrated by venous ulcers is
suggestive of an abnormality in the maintenance of tissue
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Senescence and the healing rates of venous ulcers
Andrew Stanley, MD, and Turner Osler, MD, Burlington, Vt
Objective: Premature cellular senescence has been linked to venous hypertension and may contribute to delayed healing
of venous ulcers. We hypothesized that the percentage of senescent cells in in vitro populations of fibroblasts isolated
from venous ulcers is directly related to the clinical time-to-healing.
Methods: Biopsy specimens were obtained from ulcer margins and unaffected dermal tissue of the ipsilateral thigh of
seven patients with active venous ulcers. Using explant culture techniques, we obtained populations of wound fibro-
blasts and normal fibroblasts. The percentage of senescence in these cell populations was determined with X-Gal 
(5-bromo-4-chloro-3-indolyl β-D-galactoside), which was used as a stain for B-galactosidase, a biomarker for senescent
dermal fibroblasts. The X-Gal stain is a peroxidase stain for B-galactosidase. All patients in the study were treated with
compression dressings. On a weekly basis, digital images were taken until ulcers healed. Planimetric healing rates were
calculated from these images, and an overall time-to-healing was recorded. All cytologic investigations were performed
on first passage cells.
Results: The average starting ulcer size was 4.2 cm2. Five of the data points represented healed ulcers. The two remain-
ing patients withdrew from the study to pursue other therapies after having been treated with compression dressings
for a long time. Linear regression analysis of healed ulcers identified a relationship between percent of senescence and
time-to-healing, which was statistically significant (R2 = 0.81, P = .037). High percentages of senescent cells also had
a correlation with slowed planimetric healing, which was not statistically significant.
Conclusions: This study demonstrates a clinical correlation between quantitative in vitro senescence and time-to-healing.
A percentage of senescence that is greater than 15% in populations of cells isolated from venous ulcers may identify a
“difficult to heal” ulcer. There is no good clinical indicator for determining the likelihood of ulcer healing, but these
results indicate that senescence percentage may have potential in this regard. (J Vasc Surg 2001;33:1206-11.)
lines. Premature fibroblast aging could also explain the
slowed healing of these ulcers.
In this study we looked to establish a relationship
between the degree of senescence in populations of cells
isolated from these ulcers and time-to-healing of the
ulcers. We think that senescence can be used as a marker
to identify “slow healers.” Designated patients would then
be eligible for other therapies that are reported to be effec-
tive in ulcers refractory to compression dressings.
METHODS
The study was approved by the Committee for
Human Research at the University of Vermont. All
patients with venous ulcers were interviewed and exam-
ined. Nine patients agreed to the study and were enrolled.
Clinical evaluation of the severity of venous disease in
enrolled patients was determined with the guidelines pre-
pared by the Executive Committee of the American
Venous Forum (Clinical Classification and Grading of
Chronic Venous Disease).15 Patient exclusion criteria
included patients in whom concomitant arterial disease
was suspected as evidenced by absent pulses or an
ankle/brachial index less than 0.8; patients who were clin-
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ically immunosuppressed (HIV, AIDS) or taking immuno-
suppressives; patients who were diabetic and patients with
a history of cancer or being treated for cancer; and all
patients younger than 18 years. Tissue cultures of two
patients eventually became contaminated before we could
complete testing. Seven patients completed all phases of
the study (Table I).
Biopsy and cell culture techniques. Enrolled
patients underwent two 4-mm punch biopsies. One
biopsy specimen was taken from the uninvolved skin of the
proximal thigh and the second from the venous ulcer bor-
der. The techniques used to isolate and culture the dermal
fibroblast are described in detail.10 The biopsy specimens
were treated with a 5-minute povidone-iodine bath fol-
lowed by a 5-minute bath in 70% ethanol solution. The
specimens were then subject to overnight incubation at
4°C in a trypsin solution (1 µg/mL), which allowed for
the separation of the dermal tissue from the epidermal and
adipose tissue. The dermal tissue was isolated under ster-
ile conditions, cut sharply into 1- to 2-mm fragments, and
placed in etched plastic culture dishes (Fisher, Pittsburgh,
Pa). A standard, complete medium consisting of Dulbecco
modified Eagle medium with 10% calf serum and antibi-
otic solution (penicillin, methicillin, amphotericin B
[Fungizone], and streptomycin) was added to support cell
growth. Two separate fibroblast populations were gener-
ated from each subject, the proximal fibroblasts (normal
fibroblasts) and wound fibroblasts (wound-fbs). The two
populations were then harvested. All further cytologic
investigations were performed on first passage cells.
Senescence-associated β-galactosidase activity.
The SA-β-Gal staining is well described in a study by
Dimri et al in 1995.16 Immediately after they were har-
vested, first passage cells were prepared for staining.
Cells were allowed to incubate overnight at 37°C on a
p100 dish. During this time, cells settled and fastened
themselves to the culture dish. After being fixed with a
3% formaldehyde solution, the fibroblasts were washed
Fig 1. Digital image of venous ulcer with cloth ruler as reference
for surface area measurements.
Fig 2. Senescence versus healing in weeks. Squares () denote
patients who participated until ulcer healing. Triangles () refer
to patients who withdrew to seek other therapies. Linear regres-
sion analysis noted a statistically significant relationship (P = .037).
with phosphated buffer solution and incubated
overnight at 37°C (atmospheric carbon dioxide) with
fresh senescence-associated β-Gal (SA-β-GAL) stain
solution (1 mg of 5-bromo-4-chloro-3-indolyl β-D-
galactoside [X-Gal]) per milliliter/40 mm citric acid
sodium phosphate, pH 6.0/5 mm potassium ferro-
cyanide/5 mm potassium ferricyanide/5 mm potassium
ferrocyanide 150 mm sodium chloride/2 mm magne-
sium chloride. Staining was evident in 8 to 10 hours and
maximal at 18 to 36 hours. Senescent cells displayed a
perinuclear precipitation of blue dye. This allowed for a
clear identification with standard light microscopy. The
percentage of positive SA-β-Gal cells was determined
after a count of 300 cells per dish. Cells were stained 24
hours after plating out. These populations were less than
20% confluent. Each 100× power field contained
approximately 20 to 30 cells.
Clinical follow-up of venous ulcers time-to-healing.
After biopsy, patients visited the clinic for weekly paste
compression dressing (Gelocast; Beiersdorf Inc, Norwalk,
Conn). The time-to-healing is the number of weeks
required before the patient clinically healed.
Clinical follow-up of venous ulcers with digital
imaging. During each weekly visit for compression dress-
ing applications, digital images were taken with a Sony
Mavica MVC FD-91 digital camera (Tokyo, Japan) and
analyzed with Image-Pro Plus 4.1 (Media Cybernetics,
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Silver Spring, Md). A cloth ruler was draped over the ulcer
at the time of the photo so that a size reference was part
of the digital image (Fig 1). Changes in surface area were
determined over the time required to heal the ulcer. All
planimetric data were collected by a blinded observer.
Statistical analyses. The significance (P value) and
strength (r2) of all analyses except for those in Table II were
assessed with the least squares linear regression (Minitab
13.1, State College, Pa). Table II significance (P value) was
assessed with a paired Student t test.
RESULTS
All patients enrolled had CEAP C6 lesions. Nine
patients agreed to participate in this study. Of the nine
patients, two had bacterial contamination of their tissue
cultures. This rate of contamination is similar to earlier
studies in which 16% to 25% of cultures became contami-
nated. Seven patients were enrolled in the time-to-healing
arm study. In the course of follow-up, two patients with-
drew after being treated for a long time in paste compres-
sion boots. One left to pursue HCS application; another
lived a long distance from the clinic and opted for com-
pression stockings and local wound care.
Digital imaging of the ulcers was initiated after the
first patient had completed treatment, and thus, planimet-
ric data were only available on six patients. Of the enrolled
patients (Table I), five were women and two were men.
The average age was 52.3 years. The group included
patients with recurrent ulcers and first-time ulcerations.
Some patients had prior deep venous thromboses, and
some had significant trauma to the affected leg. Because of
the low number of patients, these epidemiologic variables
had no statistically significant effect on time-to-healing or
planimetric healing.
Senescence rates of cell populations. In all patients,
wound-fb populations had a higher percentage of senes-
cent cells than did normal fibroblast populations (Table
II). In fact, in all patients, the wound-fb populations had
at least a 10-fold increase in the rate of senescent fibro-
blasts than the populations of fibroblasts cultured from the
uninvolved tissue of the ipsilateral leg (P = .0001).
Time-to-healing. There was good correlation be-
tween the percentage of senescent cells in isolated popula-
tions of wound-fb and time to healing. This relationship
Table I. Patient and ulcer characteristics
Pt Age (y) Sex Recurrent Prior DVT Trauma Pedal pulse/ABI CEAP
KM 43 F Y N N Palp C6EP
BB 52 F Y Y N Palp C6ES
SK 32 M N N N Palp C6EP
AS 52 F Y Y Y Palp C6ES
OB 56 F N N Y Palp C6ES
RG 46 M Y Y Y 0.95 C6ES
FF 88 F N N N Palp C6EP
ABI, Ankle/brachial index; DVT, deep venous thrombosis; F, female; M, male; N, no; Palp, palpation; Pt, patient; Y, yes.
Table II. Difference in senescence rates between popu-
lations of fibroblasts isolated from tissue biopsies of
venous ulcers (wound) and the ipsilateral thigh 
(normal)*
Pt Normal Wound
KM 1% 14.9%
BB 1% 12.6%
SK 0.33% 4.0%
AS 0.66% 17.6%
OB 1.33% 14.3%
RG 0.33% 21%
FF 2.33% 26.3%
*P = .0001.
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was examined through linear regression and was noted to
be statistically significant (R2 = 0.77; P = .037) (Fig 2).
Planimetric healing versus senescence. There was no
linear correlation noted between rates of healing versus a
percentage of senescent cells in populations of wound-fb
(P = .497) (Fig 3). However, in the three patients in whom
the senescent rate of explant populations was 15% or
higher, slow rates of healing were noted (healing rates were
close to 0 or ulcers actually grew [positive healing rates]).
Ulcer size. Initial ulcer size did not correlate well
with rate of ulcer healing or time to healing (Figs 4 and 5).
DISCUSSION
The current therapies for venous ulcers include a vari-
ety of compression dressings, growth factors, and autoge-
nous skin grafting as well as HCS grafting. Both
platelet-derived growth factor and HCS have been her-
alded as useful in treating “difficult ulcerations.”5,17 The
problem lies in the early identification of difficult ulcera-
tions. The most common definition of difficult ulcer is an
ulcer that fails to heal during a given time period of tradi-
tional therapy (usually compression dressings). As previ-
ously mentioned, compression dressings often require
months for an ulcer to heal successfully. By definition,
patients with ulcers that are difficult to heal have under-
gone months of ineffective treatment. Most of these
patients are not hospitalized, and the morbidity and
inconvenience of months of compression dressings do not
carry an easily definable cost. The cost of growth factor
therapy and HCS makes widespread use prohibitive. The
purpose of this study was to see if cellular senescence could
be used as a clinical indicator to identify ulcers that were
difficult to heal on clinical presentation. Early identifica-
tion of ulcers that are difficult to heal allows the clinician
to direct these patients to the appropriate therapies. In our
small populations of patients it is not possible to identify
an exact level of senescence that would be suggestive of
delayed healing. However, with many more patients, it is
possible to see how such a level could be used to deter-
mine patients with slow-healing ulcers.
Fig 4. Ulcer size versus time to heal. Data were not statistically
significant with P = .670 (r2 = 0.0).
Fig 5. Ulcer size versus healing rate. Data were also not statisti-
cally significant with P = .117 (r2 = 37.3).
Fig 3. Plainimetric data were used to generate healing rate (square centimeter [Cm2] per week). In the case where
ulcers healed and became smaller, a negative value is representative. In cases where ulcers grew, positive values were
generated. Linear regression was used to investigate these data, but statistical significance was not noted (P = .497).
JOURNAL OF VASCULAR SURGERY
1210 Stanley and Osler June 2001
A significant relationship between senescence rates
and time-to-healing was noted. However, the results of
planimetric data did not correlate as well. We had hoped
to note a better correlation between senescence rate and
healing rate per unit of surface area (square centimeter).
We did not observe this with statistical significance.
Statistically significant relationships between ulcer size on
presentation and time to healing or rate of healing were
not noted. This is contrary to recent published
reports.18,19 Our low number of patients makes statistical
confirmation of our observations of limited value. It 
is possible that with more patients we could identify 
a threshold of senescence that would identify a 
“slow healer” population. These patients could then be
treated on presentation with other modalities. Simple two-
dimensional planimetric data do not account for ulcer
depth. Three-dimensional analysis of these ulcers may be a
better assessment for a healing rate.
Many patients were reluctant about undergoing an
ulcer biopsy because they had been trying to heal their
ulcer for weeks to months and refused enrollment, and
consequently, our patient numbers were low. Larger num-
bers of both slowly healing ulcers and rapidly healing
ulcers would have added weight toward our conclusions.
Because the senescence data per patient took weeks to
generate, there is really little clinical utility to the test. The
relationship between senescence rates and slowed healing
does encourage the investigation of a “quick prep” test,
which would yield similar data in a matter of hours or days
with the staining of the biopsy specimens directly. This
would direct patients with difficult to heal ulcers toward
alternative therapies early on in their course of treatment.
At the cell and molecular level, it has yet to be deter-
mined what factor or factors lead to the accelerated aging
and premature senescence seen in tissue subject to venous
hypertension. Possible factors include elevated tissue pres-
sure and white cell activation.
CONCLUSION
The data collected in this small prospective pilot study
further support the relationship between chronic venous
hypertension and premature fibroblast aging. The exact
mechanism by which these cells become prematurely
senescent is not yet clear. The data also show that the
degree of senescence in populations of fibroblasts isolated
from patients with CVI and active ulcers may be predictive
of time-to-healing.
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Dr Thomas O’Donnell, Jr (Boston, Mass). First, I want to
congratulate you on addressing biological questions associated
with chronic venous disease. I am sure it makes your mentor, Dr
Menzoian, quite happy to see you continuing the work that you
started at Boston University, which you presented initially at the
American Venous Forum. I am pleased to see you building on
what you started.
As a senior member of this society I am qualified to talk a lit-
tle bit about senescence. I was curious that apparently you did not
determine the actual starting size of the ulcers. Some investigators
might debate that there is an important clinical predictor of ulti-
mate ulcer healing, which is the initial size of the wound. Several
large European studies have shown clearly that large ulcers fail to
heal and in addition that the rate of wound closure is slower for
large ulcers when compared with smaller ulcers. If you have the
initial ulcer size in the manuscript, you might comment on its
impact on healing rates.
Second, in an effort to standardize the reporting of venous
results, the CEAP classification is favored. You did report the C
of CEAP, but could you tell us a little bit about the E, A, and P
(the etiology, anatomy, and physiology) of your patient popula-
tion? Did you do any hemodynamic studies such as valve closure
times or air plethysmography that might show some physiologic
differences among your patients?
Third, did you perform venograms or duplex imaging to
visualize occluded segments or other characteristics that might
help to classify your patients as primary valvular incompetence or
post-thrombotic in type?
Finally, some of us would debate that elastic compression is
the only viable alternative to heal venous ulcers. Some surgeons
do operate on patients with venous ulcers.
I enjoyed your paper and particularly the school colors of
green and yellow that many of us associate with the University of
Vermont. Thank you.
Dr Andrew Stanley. Thanks, Dr O’Donnell, for your many
comments. We did not do any physiologic testing. It becomes
problematic in terms of getting this paid for and getting it by the
various IRBs, and I did not do any of that. That is a blank part of
our presentation. Starting this study out, I did want to look at the
cytologic variables in terms of their ability to predict healing, and
that is certainly a piece of the puzzle that I would like to put in
but it is kind of difficult to arrange that.
Second, you had commented on ulcer size. That is part of the
manuscript. We thought we covered ulcer size in terms of surface
area per week, and they probably are independent variables and
we should probably include that, too.
Dr Jens Eldrup-Jorgensen (Portland, Me). Andy, I would
like to compliment you on a very nice presentation. The question
I have is whether you have had any patients status post venous
reconstruction, SEPS, or other physiologic reconstruction, and
have been able to measure the senescence before and afterwards.
Dr Stanley. We have not done any. Looking at senescence of
these ulcers before and after treatment is certainly the next step to
look at the mechanism and see if you can clear that. Senescence in
vivo is purportedly an irreversible process. One of the therapies that
I think—again this is a personal bias—is helpful is the new Apligraf.
It is reported as one of new lightning strikes for venous disease, but
it makes sense along with some of my research. I believe these cells
are aged, if not senescence, but it is a heterogeneous population.
The senescent cells do not respond well to growth and that would
be important in terms of following up on the senescence rate to see
if the senescence rate is reduced after the Apligraf is reduced.
I do not have any data based upon SEPS following these
ulcer therapies.
Dr William Babson, Jr. (Plymouth, Mass). Two points. One
is, with the senescence concept. It makes sense then that surgical
debridement of these ulcers might bring new cells into the wound
that are not senescent that might help to heal, and we all know
that debridement does seem to help wounds heal. That could be
an explanation of why debridement works so well. Of course,
when you talk to people about debridement, some people talk
about just debriding the necrotic tissue, whereas others talk about
actually excising the whole wound and making it larger, and they
seem to result in healing. That is one point.
The second point I have is, back in the 1970s and early
1980s, I used a lot of placental dressings on these patients, and
I thought that really helped. Unfortunately, I did not do any
good studies to show. Of course in the early 1980s because of
the HIV problem, we stopped using them, but chorion and
amnion membranes are just full of growth factors and I am
convinced that they really helped wounds to heal. In your con-
cept of senescence, if the cell does not react to growth factors,
then you have to get rid of it, whereas if you put on growth
factors and the cells are not senescent then they would respond
so that there is a question in that regard, too. Thank you.
Dr James Menzoian. (Boston, Mass). I have a comment.
Andy, I am very pleased to see that you have continued the work
that you started. I think it is important to point out that Dr
Stanley was a recipient of the Beiersdorf-Jobst Research Award,
which is a competitive research grant and, they would be pleased
to see you are continuing the work.
Just a couple of things. One is, I think the correcting for size,
Dr O’Donnell’s point, is a good one. I think centimeters per week
is good, but you can envision that a larger circumference wound
would by definition have more centimeters, so if you correct for
size that may make a difference and tighten up your data.
I think the other thing, maybe you ought to point out to the
audience what a normal level of B-gal staining is because these are
very impressive numbers.
Finally, you had done some preliminary work with frozen
sections for B-gal staining. What do you think about that as a
quicker answer for the future?
Dr Stanley. I think I need more help. As a cytopathologist I
am not good enough, but I am in the stages of asking some of the
pathologists up at our place to help us out. Certainly we have
talked about normal explant cultures, and our experience at BU
and the literature suggest that normal adult senescent rates from
explant populations are 1% or less. The neonatal fibroblast, which
is a standard that everybody uses, is close to 0%, so these per-
centages are marked elevated.
Dr David C. Brewster (Boston, Mass). Dr Stanley, in the
wound that you predict is going to be a difficult healing problem,
elaborate for us just a little bit more about what more aggressive
measures you may take. What is available?
Dr Stanley. That is a good question. That raises, well, what
good is this study? You have to believe that there is a secondary
therapy that you can use. Dr O’Donnell’s group uses SEPS. That
is something that should be investigated. The other thing that I
have a strong feeling for is Apligraf. I think that it works well. I
only have anecdotal experience with it at this point. I think I have
used it on five or six patients up there, but I think it helps. It all
depends on your personal beliefs. If you do not think that there
is a second level of therapy to go ahead and use in these patients,
well that is a valid thing. Autogenous skin grafting is something
that a lot of people use as a second level therapy.
Dr William Flynn, Jr (Arlington, Mass). I think in any dis-
cussion of slowly healing venous ulcers, it should probably be
mentioned as an afterthought that biopsy of a slowly healing ulcer
should be done, since every once in a while one is malignant.
Dr Stanley. Absolutely, that is interesting you say that. That is
one of the reasons why this whole process started out. One of the
dermatologists at BU had done some work looking at cancer
changes in venous ulcers and had noted some squamous cell as
well as basal cell changes in that.
DISCUSSION
